SCHEMBL30592183

SCHEMBL30592183

O=c1cnc2c(Br)cccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.39
AXL P30530 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
RPS6KA3 P51812 1/20 0.39
CSNK2A1 P68400 1/20 0.39
PLK3 Q9H4B4 1/20 0.39
CA12 O43570 2/20 0.38
CA9 Q16790 2/20 0.38
FEN1 P39748 1/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
GLA P06280 1/20 0.35
PMP22 Q01453 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PARP1 P09874 1/20 0.35
CA1 P00915 1/20 0.34
CA3 P07451 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1041260 0.78 KDM4E (0.42) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL3942822 0.78 MAPKAPK2 (0.46) MAPKAPK2RPS6KA3CSNK2A1PLK3CA12
SCHEMBL21530547 0.78 PARP1 (0.42) MAPKAPK2RPS6KA3CSNK2A1PLK3CA12
SCHEMBL2359356 0.78 PSMB8 (0.45) NOS1MAPKAPK2RPS6KA3CSNK2A1PLK3
SCHEMBL29650339 0.78 PSMB8 (0.45) NOS1MAPKAPK2RPS6KA3CSNK2A1PLK3
SCHEMBL13723653 0.78 ADORA3 (0.44) PDE3BPDE3AALDH1A1PARP1
SCHEMBL30196908 0.78 PARP1 (0.42) MAPKAPK2RPS6KA3CSNK2A1PLK3CA12
SCHEMBL30297094 0.75 MAPKAPK2 (0.40) MAPKAPK2RPS6KA3CSNK2A1PLK3PDE3B
SCHEMBL18739120 0.74 DYRK1A (0.41) MAPKAPK2RPS6KA3CSNK2A1PLK3PDE3B
SCHEMBL4524595 0.74 ADORA3 (0.52) NOS1ALDH1A1KDM4EHSD17B10PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221988-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI), INC. (CN) 2025-07-10 US disclosed
EP-4504716-A1 COMPOUNDS AND METHODS OF TREATING CANCERS Cullgen (Shanghai), Inc. (CN) 2025-02-12 EP disclosed
CN-119156381-A Compounds and methods for treating cancer 上海睿跃生物科技有限公司 2024-12-17 CN disclosed
WO-2024149189-A1 AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 浙江海正药业股份有限公司 2024-07-18 WO disclosed
WO-2023193760-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221988-A1 COMPOUNDS AND METHODS OF TREATING CANCERS GSPT1, GSS, G6PC1 NOS1 1108/4885AXL 2739/4885MAPKAPK2 4205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.